U.S. patent application number 11/044285 was filed with the patent office on 2005-11-17 for quorum sensing and biofilm formation.
This patent application is currently assigned to The Regents of the University of California. Invention is credited to Anderson, Maxwell H., Merritt, Justin, Shi, Wenyuan.
Application Number | 20050255128 11/044285 |
Document ID | / |
Family ID | 29710210 |
Filed Date | 2005-11-17 |
United States Patent
Application |
20050255128 |
Kind Code |
A1 |
Merritt, Justin ; et
al. |
November 17, 2005 |
Quorum sensing and biofilm formation
Abstract
The present invention is based on the discovery that
interspecies quorum sensing is related to biofilm formation. The
present invention provides methods useful for treating or
preventing biofilm formation and microbial infections associated
with biofilm formation by using an agent that either increases
LuxS-dependent pathway or interspecies quorum sensing signal. The
present invention also provides compositions containing an
anti-micorbial agent and an agent that either increases
LuxS-dependent pathway or interspecies quorum sensing signal.
Inventors: |
Merritt, Justin; (Los
Angeles, CA) ; Shi, Wenyuan; (Los Angeles, CA)
; Anderson, Maxwell H.; (Seattle, WA) |
Correspondence
Address: |
MORGAN, LEWIS & BOCKIUS LLP (SF)
2 PALO ALTO SQUARE
PALO ALTO
CA
94306
US
|
Assignee: |
The Regents of the University of
California
Oakland
CA
C3 Scientific Corporation
Seattle
WA
|
Family ID: |
29710210 |
Appl. No.: |
11/044285 |
Filed: |
January 26, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11044285 |
Jan 26, 2005 |
|
|
|
10164446 |
Jun 6, 2002 |
|
|
|
Current U.S.
Class: |
424/200.1 ;
514/192; 514/2.3; 514/200; 514/253.08; 514/3.1 |
Current CPC
Class: |
A61K 38/1709
20130101 |
Class at
Publication: |
424/200.1 ;
514/008; 514/192; 514/200; 514/253.08 |
International
Class: |
A61K 039/40; A61K
039/02; A61K 031/43; A61K 031/497; A61K 031/496; A61K 038/14 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 4, 2003 |
WO |
PCT/US03/17850 |
Claims
What is claimed is:
1. A composition comprising an anti-microbial agent and an agent
that increases LuxS-dependent signal pathway in a bacterium.
2. A composition comprising an anti-microbial agent and an agent
that increases an interspecies quorum sensing signal.
3. The composition of claim 1, wherein the agent increases an
interspecies quorum sensing signal.
4. The composition of claim 1, wherein the agent is an interspecies
quorum sensing signal.
5. The composition of claim 1, wherein the agent is
autoinducer-2.
6. The composition of claim 1, wherein the agent is LuxS.
7. The composition of claim 1, wherein the agent increases the
activity of LuxS in interspecies quorum sensing.
8. The composition of claim 1, wherein the anti-microbial agent is
an antibiotic.
9. The composition of claim 8, wherein the antibiotic is selected
from the group consisting of penicillin, quinoline, vancomycin, and
sulfonamide.
10. The composition of claim 8, wherein the antibiotic is selected
from the group consisting of ampicillin, ciprofloxacin, and
sulfisoxazole.
11. The composition of claim 8, wherein the anti-microbial agent
comprising a targeting moiety and an anti-microbial peptide moiety,
wherein the targeting moiety is coupled to the anti-microbial
peptide moiety and recognizes a target microbial organism and
wherein the composition has an anti-microbial effect on a target
microbial organism.
12. The composition of claim 8 further comprising a
pharmaceutically acceptable carrier.
13. A method of treating a disease condition associated with
bacterial biofilm formation comprising administering to a subject
in need of such treatment the composition of claim 1.
14. The method of claim 13, wherein the disease condition is on an
epithelial or a mucosal surface.
15. The method of claim 14, wherein the mucosal surface is selected
from the group consisting of mouth, vagina, gastrointestinal tract,
and esophageal tract.
16. The method of claim 13, wherein the disease condition is an
oral infection.
17. The method of claim 13, wherein the disease condition is caused
by S. mutans.
18. A method of treating a microbial infection associated with
biofilm formation comprising administering to a population of
bacteria an anti-microbial agent and an agent that increases
LuxS-dependent signal pathway in a bacterium.
19. A method of treating microbial infection associated with
biofilm formation comprising administering to a population of
bacteria an anti-microbial agent and an agent that increases
interspecies quorum sensing signal.
20. A method of treating bacterial biofilm formation on a surface
comprising contacting the surface with an anti-microbial agent and
an agent that increases LuxS-dependent signal pathway in a
bacterium.
21. A method of treating bacterial biofilm formation on a surface
comprising contacting the surface with an anti-microbial agent and
an agent that increases interspecies quorum sensing signal.
22. A method of preventing or inhibiting bacteria biofilm formation
or sensitizing bacteria for an anti-bacteria treatment comprising
administering an agent to a population of bacteria, wherein the
agent increases LuxS-dependent signal pathway in a bacterium.
23. A method of preventing or inhibiting bacteria biofilm formation
or sensitizing bacteria for an anti-bacteria treatment comprising
administering an agent to a population of bacteria, wherein the
agent increases interspecies quorum sensing signal.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 10/164,446, filed Jun. 6, 2002 which is
incorporated herein by reference in its entirety for all
purposes.
FIELD OF THE INVENTION
[0002] This invention relates generally to the field of biofilm
formation, especially bacterial biofilm formation associated with
interspecies quorum sensing.
BACKGROUND OF THE INVENTION
[0003] A bacterial biofilm is a community of bacteria (either
single or multiple bacterial species) that adhere to a solid
surface (Davey, M. E., et al., Microbiol Mol Biol Rev, 64:847-67
(2000)). In recent years, biofilms have received much attention due
to their impact on industry and medicine. Biofilms are responsible
for a plethora of problems ranging from biofouling of pipelines to
facilitating tissue damage in Cystic Fibrosis patients (Barbeau,
J., et al., Can J Microbiol, 44:1019-28 (1998)); Stickler, D., Curr
Opin Microbiol, 2:270-5 (1999)); and Wen, Z. T., et al., Appl
Environ Microbiol, 68:1196-203 (2002)).
[0004] Studies have clearly shown that a bacterial biofilm is not a
result of random accretions of bacterial cells; rather, it is the
net result of a community of bacteria cooperating to form
well-differentiated structures (Costerton, J. W., et al., Annu Rev
Microbial, 64:847-67 (2000)). The production of biofilm is
dependent on the progression through several steps, from initial
attachment to full maturity as a stable ecologic system (Pratt, L.,
et al., Curr Opin Microbiol, 2:598-603 (1999)). Given the
tremendous metabolic and physiological changes that are required
for the switch from planktonic to biofilm growth, it would seem
reasonable that there exist some gene regulators responsible for
facilitating this process. Indeed various gene regulation systems
have been found to be involved in bacterial biofilm formation
(Davies, D. G., et al., Science, 280:295-8 (1998)).
[0005] Quorum sensing is a mechanism for bacteria to change gene
expression at very specific cell densities. To date, there are two
types of recognized quorum sensing systems in bacteria. The first,
known as intraspecies quorum systems, are species specific. In
Gram-negative bacteria, intraspecies quorum signals are composed of
an acyl-homoserine lactone backbone with species specific
substitutions, while Gram-positive bacteria use various peptides as
their signals (Dunny G. M., et al., Annu Rev Microbiol, 51:527-64
(1997); Fuqua, C., et al., Curr Opin Microbiol, 1:183-9 (1998); and
Parsek, M. R., et al., Proc Natl Acad Sci USA, 97:8789-93
(2000)).
[0006] Recently, a second quorum sensing system was characterized
in Vibrio harveyi. This system is referred to as the interspecies
quorum system and is believed to operate as a universal quorum
system for many bacteria possessing the characteristic luxS gene
(Bassler, B. L., Curr Opin Microbiol, 2:582-7 (1999); Schauder, S.,
et al., Mol Microbiol, 41:463-76 (2001); and Surette, M. G., et
al., Proc Natl Acad Sci USA, 96:1639-44 (1999)). The luxS gene is
highly conserved among many species of Gram-negative and
Gram-positive bacteria and is thought to be responsible for
synthesizing a universally recognized quorum signal referred to as
autoinducer-2 (AI-2) (Surette, M. G., et al., Proc Natl Acad Sci
USA, 96:1639-44 (1999)). The chemical structure of the actual
signal is still under investigation, however, crystallographic
studies of the AI-2 receptor in Vibrio harveyi seem to suggest that
AI-2 is a furanosyl borate diester formed from the metabolite
4,5-dihydroxy-2,3-pentadione (Chen, X., et al., Nature, 415:545-9
(2002); Ruzheinikov, S. N., et al., J Mol Biol, 313:111-22 (2001);
and Schauder, S., et al., Mol Microbiol, 41:463-76 (2001)).
[0007] One feature regarding quorum sensing that has been
extensively studied, is the link between intraspecies quorum
sensing and biofilm related gene expression. There are several
well-characterized examples for the involvement of intraspecies
quorum sensing and biofim formation. For example, lasI of
Pseudomonas aeruginosa directs the synthesis of an acyl-homoserine
lactone signal molecule used for P. aeruginosa intraspecies quorum
signaling (Davies, D. G., et al. Science, 280:295-8 (1998)).
Mutants in this gene were unable to produce biofilms that
progressed beyond the very early stages of biofilm development
(Davies, D. G., et al. Science, 280:295-8 (1998)). However,
exogenous addition of the appropriate signal complemented the
defect (Davies, D. G., et al. Science, 280:295-8 (1998)).
[0008] A similar result was also obtained due to inactivation of
the cep intraspecies quorum sensing system of Burkholderia cepacia
(Huber, B., et al., Microbiology, 147:2517-28 (2001)). Furthermore,
a transposon mutagenesis study of the oral pathogen Streptococcus
gordonii had detected a severe biofilm deficiency due to disruption
of the two component system required for its intraspecies quorum
sensing system (Loo, C. Y., et al., J Bacteriol, 182:1374-82
(2000)).
[0009] In Staphylococcus aureus, intraspecies quorum signaling has
been implicated as a negative regulator of biofilm formation
(Vuong, C., et al., JInfect Dis, 182:1688-93 (2000)).
LuxS-dependent AI-2 signals have also been detected in a variety of
bacterial species and found to be involved in various cellular
processes in a cell density dependent manner (Day, W. A., Jr., et
al., Infect Immun, 69:15-23 (2001); Forsyth, M. H., et al., Infect
Immun, 68:3193-9 (2000); Frias, J., et al., Infect Immun, 69:3431-4
(2001); Joyce, E. A., et al., J Bacteriol, 182:3638-43 (2000);
Lyon, W. R., et al., Mol Microbiol, 42:145-57 (2001); and
Sperandio, V., et al., Proc Natl Acad Sci USA, 96:15196-201
(1999)).
[0010] S. mutans is a major cariogenic bacterium that normally
inhabits a complex, multispecies, biofilm on the tooth surface
(dental plaque) (Tanzer, J. M., et al., JDent Educ, 65:1028-37
(2001)). The bacteria produce large amounts of exopolysacchrides,
especially in the presence of sucrose, that enable them to adhere
to the tooth.
[0011] The bacteria also have the ability to produce large amounts
of acids from fermentable sugars in the diet. Acid accumulation can
eventually dissolve the hard, crystalline structure of the tooth
resulting in a carious lesion (Quivey, R. G., et al., Crit Rev Oral
Biol Med. 12:301-14 (2001)). Previous studies have established some
sophisticated interactions among the oral streptococci as well as
with other oral bacteria within the same dental plaque
(Kolenbrander, P. E., Enzymol, 253:385-97 (1995); Kolenbrander, P.
E., Annu Rev Microbiol, 54:413-37 (2000); and Kolenbrander, P. E.,
et al., Infect Immun, 63:4584-8 (1995)).
[0012] There is a need in the art to develop methods and
compositions useful for regulating biofilm formation, especially
preventing or treating biofilm formation in association with
microbial infections.
SUMMARY OF THE INVENTION
[0013] The present invention is based on the discovery that
interspecies quorum sensing, e.g., LuxS-dependent signal pathway is
related to biofilm formation. Accordingly the present invention
provides methods for preventing or inhibiting biofilm formation and
methods for treating or preventing disease and other conditions
associated with biofilm formation. The present invention also
provides compositions that are useful for treating microbial
infections and infestations associated with biofilm formation.
[0014] In one embodiment, the present invention provides a method
of preventing or treating the formation of a biofilm on a surface.
The method comprises contacting the surface with an agent that
increases LuxS-dependent signal pathway in a bacterium or increases
an interspecies quorum sensing signal.
[0015] In another embodiment, the present invention provides a
method of treating or preventing a disease condition associated
with a biofilm. The method comprises administering to a subject in
need of such treatment an agent, wherein the agent increases
LuxS-dependent signal pathway in a bacterium or increases an
interspecies quorum sensing signal.
[0016] In yet another embodiment, the present invention provides a
composition comprising an anti-microbial agent and an agent that
increases LuxS-dependent signal pathway in a bacterium or increases
an interspecies quorum sensing signal.
[0017] In still another embodiment, the present invention provides
a method of treating a disease condition associated with bacterial
biofilm formation comprising administering to a subject in need of
such treatment the composition of the present invention.
[0018] In another embodiment, the present invention provides a
method of treating a microbial infection associated with biofilm
formation. The method comprises administering to a population of
bacteria an anti-microbial agent and an agent that increases
LuxS-dependent signal pathway in a bacterium or increases
interspecies quorum sensing signal.
[0019] In yet another embodiment, the present invention provides a
method of treating bacterial biofilm formation on a surface. The
method comprises contacting the surface with an anti-microbial
agent and an agent that increases LuxS-dependent signal pathway in
a bacterium or increases interspecies quorum sensing signal.
[0020] In another embodiment, the present invention provides a
method of preventing or inhibiting bacteria biofilm formation or
sensitizing bacteria for an anti-bacteria treatment. The method
comprises administering an agent to a population of bacteria,
wherein the agent increases LuxS-dependent signal pathway in a
bacterium or increases interspecies quorum sensing signal.
SUMMARY OF THE FIGURES
[0021] FIG. 1 shows an alignment of the S. mutans LuxS protein (SEQ
ID NO. 1) and several other representative LuxS proteins. Residues
that coordinate a Zn.sup.2+ ion and comprise the catalytic center
of LuxS (H, H, & C) are printed in bold. 1, V.sub.--harveyi
(SEQ ID NO. 2); 2, S_mutans; 3, E.sub.--coli (SEQ ID NO.3); 4,
S.sub.--pyogenes (SEQ ID NO. 4); 5, B.sub.--subtilis (SEQ ID
NO.5).
[0022] FIG. 2 shows S. mutans luxS complements a frameshift
mutation in E. coli DH5.alpha.. E. coli DH5.alpha. was transformed
with an E. coli-S. mutans shuttle vector containing an intact copy
of the S. mutans luxS gene (pLuxSm). This strain was examined for
AI-2 production using the luminescence based AI-2 reporter assay.
V. harveyi strain BB 170 (sensor 1.sup.-, sensor 2.sup.+) served as
a positive control, while E. coli DH5.alpha. served as a negative
control. Luminescence is expressed as fold induction relative to
the background values.
[0023] FIG. 3 shows AI-2 induction in the presence or absence of
sugar. S. mutans was grown and assayed as described in Materials
and Methods. Cells were grown overnight and resuspended to an
OD.sub.600 of 0.4 in reporter assay (AB) media and incubated with
aeration for 3 hours at 37.degree. C. One sample was incubated in
AB alone, while the other had sucrose added to a final
concentration of 1%. The presence of sucrose in the media caused a
potent reduction in luminescence to below background values.
[0024] FIGS. 4A and 4B show luxS knockout in S. mutans. FIG. 4A
illustrates the knockout procedure. Plasmids containing either
cloned fragments of S. mutans DNA as well as the erythromycin
cassette were cut using the indicated restriction sites and then
ligated into a linearized pUC 19 backbone. The resulting construct
was linearized with the unique AatII site and transformed into S.
mutans for double crossover. FIG. 4B shows that AI-2 production
assay confirms that activity was lost in the mutant.
[0025] FIG. 5 shows the results of biofilms tested for their
ability to resist detergent treatment with SDS. Three samples of
wildtype and mutant biofilms grown on glass coverslips were shaken
at 150 rpm for one hour. The OD.sub.600 of the resulting
supernatants were compared.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] The present invention relates in general to the interspecies
quorum sensing, LuxS-dependent signal pathway and their association
with biofilm formation. It is the discovery of the present
invention that increasing interspecies quorum sensing signal or
LuxS-dependent signal pathway decreases biofilm formation and
increases biofilm's sensitivity to anti-microbial treatment. The
present invention provides methods and compositions useful for
preventing or treating biofilm formation or microbial infections
associated with bioflim formation.
[0027] One feature of the present invention provides a method for
preventing or treating biofilm formation. According to the present
invention, the formation of a biofilm on a surface can be prevented
or treated by contacting the surface, e.g., a biological surface or
an inanimate or dynamic solid industrial surface such as a heat
exchanger or "clean room" surfaces with an agent or administering
an agent to a subject, e.g., a human or an animal in need of such
treatment, wherein the agent either increases LuxS-dependent signal
pathway in a bacterium or increases an interspecies quorum sensing
signal. Alternatively, such agent can be administered to a
population of bacteria, e.g., more than one bacterium to prevent or
decrease the biofilm formation of the bacteria.
[0028] According to another feature of the present invention,
bacteria, biofilms, or surfaces containing thereof can be
sensitized for anti-microbial, e.g., anti-bacteria treatment using
the agents of the present invention. For example, the agents of the
present invention can be administered to a population of bacteria
or bacteria within a biofilm so that these bacteria are primed or
sensitized to be less resistant or more susceptible to
anti-microbial treatments, e.g., antibiotics, target specific
therapeutic agents, detergents, and biocides.
[0029] Bacteria or biofilms can be sensitized either prior to or
simultaneously with any anti-microbial treatment. For example, the
agents of the present invention can be used prior to or in
combination with an anti-microbial agent to treat a surface, e.g.,
industrial or biological surface or subject, e.g., human for
biofilm formation or microbial infections such as bacterial
infection associated with biofilm formation. The subject in need of
such treatment can be any suitable subject, e.g., a human or an
animal including a domestic animal such as a horse, dog, or
cat.
[0030] The agent of the present invention can be any agent known or
later discovered that is suitable for the present invention. For
example, such agent can be any entity capable of activating the
LuxS gene, any expression product of the LuxS gene that is involved
in the interspecies quorum sensing, any down stream component in
the LuxS-dependent signal pathway including any interspecies quorum
sensing signal itself, or any agent capable of increasing the
function or activity of an interspecies quorum sensing signal.
[0031] In one embodiment, an agent that increases LuxS-dependent
signal pathway is LuxS protein which includes full-length LuxS
protein and one or more partial LuxS proteins having substantially
the same function of the full-length LuxS protein in synthesizing
interspecies quorum sensing signal, e.g., autoinducer-2 in a
bacterium. In another embodiment, an agent that increases an
interspecies quorum sensing signal is autoinducer-2 which includes
autoinducer-2 and an analog or derivative thereof functioning as an
interspecies quorum sensing signal or having the same or similar
function of autoinducer-2 in interspecies quorum sensing. For
example, WO 01/85664 discloses various autoinducer-2 analogs which
could be suitable for the present invention.
[0032] The methods provided by the present invention can be used to
prevent or treat any biofilm. Biofilms in general are coatings
formed via bacteria adhering to a surface, e.g., solid surface.
Usually a population of bacteria interact or signal with each other
directly or indirectly to form a highly hydrated matrix of
exopolymers, typically polysaccharide, and other biopolymers on a
surface: The formation of biofilm could take several steps and
usually includes initial attachment and full maturity into a stable
community.
[0033] According to the present invention, biofilms prevented or
treated by the present invention can contain single species or
multiple species bacteria. In one embodiment, the biofilms are
associated with microbial infection or a disease condition
including, without limitation, dental caries, periodontal disease,
prostatitis, osteomyelitis, septic arthritis, and cystic fibrosis.
In another embodiment, the biofilms contain Gram positive bacteria
including without limitation Streptococcus, e.g. S mutans. In yet
another embodiment, the extracellular matrix or exopolymers of the
biofilms is regulated by or responsive to LuxS-dependent
interspecies quorum sensing.
[0034] In still another embodiment, the biofilms are associated
with a surface, e.g., a solid surface. Such surface can be the
surface of any industrial structure, e.g., pipeline or the surface
of any structure in animals or humans. For example, such surface
can be any epithelial surface, mucosal surface, or any host surface
associated with bacterial infection, e.g., persistent and chronic
bacterial infections. The surface can also include any surface of a
bio-device in animals or humans, including without limitation,
bio-implants such as bone prostheses, heart valves, and
pacemakers.
[0035] In addition to surfaces associated with biofilm formation in
a biological environment, the surfaces treated by the present
invention can also be any surface associated with industrial
biofilm formation. For example, the surfaces being treated can be
any surface associated with biofouling of pipelines, heat
exchangers, air filtering devices, or contamination of computer
chips or water-lines in surgical units like those associated with
dental hand-pieces.
[0036] According to yet another feature of the present invention,
it provides compositions useful for treating biofilm formation and
infections associated with biofilm formation. The composition of
the present invention contains an anti-microbial entity and an
agent of the present invention. The anti-microbial entity can be
any that is suitable for the present invention, e.g., detergents,
biocides, antibiotics or target specific therapeutic entities. The
antibiotics include, without limitation, penicillin, quinoline,
vancomycin, sulfonamide, ampicillin, ciprofloxacin, and
sulfisoxazole. The target specific therapeutic entities can include
a targeting moiety coupled to an anti-micorbial peptide moiety.
U.S. application Ser. No. 10/077,624 discloses various target
specific anti-microbial entities and is incorporated herein by
reference.
[0037] The composition or agent of the present invention can also
include one or more other non-active ingredients, e.g., ingredients
that do not interfere with the function of the active ingredients.
For example, the composition or agent of the present invention can
include a suitable carrier or be combined with other therapeutic
agents.
[0038] A suitable carrier can be a powder, encapsulated solid, or
an aqueous carrier including any safe and effective materials for
use in the compositions of the present invention. In one
embodiment, an aqueous carrier is used for the compositions of the
present invention in oral formations and includes, without
limitation, thickening materials, humectants, water, buffering
agents, abrasive polishing materials, surfactants, titanium
dioxide, flavor system, sweetening agents, coloring agents, and
mixtures thereof.
[0039] A suitable carrier can also be a pharmaceutically acceptable
carrier that is well known to those in the art. Such carriers
include, without limitation, large, slowly metabolized
macromolecules, e.g., proteins, polysaccharides, polylactic acids,
polyglycolic acids, polymeric amino acids, amino acid copolymers,
and inactive virus particles.
[0040] Pharmaceutically acceptable salts can also be used in the
composition, for example, mineral salts such as sodium or stannous
fluorides, or sulfates, as well as the salts of organic acids such
as acetates, proprionates, carbonates, malonates, or benzoates. The
composition can also contain liquids, e.g., water, saline,
glycerol, and ethanol, as well as substances, e.g., wetting agents,
emulsifying agents, or pH buffering agents.
[0041] According to another feature of the present invention, the
compositions or agents of the present invention can be used to
treat or prevent disease conditions associated with biofilm
formation. For example, an effective amount of the composition or
agent of the present invention can be administered to a subject,
e.g., a human or an animal to treat or prevent disease conditions
associated with biofilm formation. Alternatively, the agent of the
present invention and an anti-microbial agent can be administered
as separate compositions, either sequential or simultaneously to a
subject to treat or prevent disease conditions associated with
biofilm formation. Various disease conditions are associated with
biofilm formation including, without limitation, dental caries,
periodontal disease, prostatitis, osteomyelitis, septic arthritis,
cystic fibrosis, and heart valve vegetations. In one embodiment,
the disease conditions are on an epithelial surface or a mucosal
surface, e.g., mouth, vagina, gastrointestinal tract, and
esophageal tract.
[0042] In generally, an effective amount of the agent or
composition of the present invention to be administered to a
subject can be determined on a case-by-case basis. Factors to be
considered usually include the total surface area to be treated,
age, body weight, stage of the condition, other disease conditions,
duration of the treatment, and the response to the initial
treatment.
[0043] Typically, the agents or compositions used in the present
invention are prepared as a topical or an injectable, either as a
liquid solution or suspension. However, solid forms suitable for
solution in, or suspension in, liquid vehicles prior to injection
can also be prepared. The composition can also be formulated into
an enteric-coated tablet or gel capsule according to known methods
in the art. In one embodiment, the composition of the present
invention can be formulated onto the surfaces of industrial or
biological structures or as coatings thereto, e.g., coatings to
prosthetic heart valves, prosthetic hearts, vascular stents, or
prosthetic joints.
[0044] The agents or compositions of the present invention may be
administered in any way which is industrially or medically
acceptable which may depend on the condition or injury being
treated. Possible administration routes include injections, by
parenteral routes such as intravascular, intravenous, intraepidural
or others, as well as oral, nasal, ophthalmic, rectal, vaginal,
topical, or pulmonary, e.g., by inhalation. The compositions may
also be directly applied to industrial or tissue surfaces.
Sustained release, pH dependent release, or other specific chemical
or environmental condition mediated release administration is also
specifically included in the invention, by such means as depot
injections or erodible implants.
EXAMPLES
[0045] The following examples are intended to illustrate but not to
limit the invention in any manner, shape, or form, either
explicitly or implicitly. While they are typical of those that
might be used, other procedures, methodologies, or techniques known
to those skilled in the art may alternatively be used.
[0046] In this study, we demonstrate that luxS dependent quorum
sensing is involved in biofilm formation of Streptococcus mutans.
S. mutans is a major cariogenic bacterium in the multi-species
bacterial biofilm commonly known as dental plaque. An ortholog of
luxS in S. mutans was identified using the data available in the S.
mutans genome project (http://www.genome.ou.edu/smutans.html).
Using an assay developed for the detection of the LuxS-associated
quorum sensing signal Autoinducer 2 (AI-2), it was demonstrated
that this ortholog was able to complement the luxS negative
phenotype of E. coli DH5.alpha.. It was also shown that AI-2 is
indeed produced by S. mutans. AI-2 production is maximal during mid
to late-log growth in batch culture.
[0047] Mutant strains devoid of the luxS gene were constructed and
found to be defective in producing AI-2 signal. There are also
marked phenotypic differences between wildtype and the luxS
mutants. Microscopic analysis of in vitro grown biofilm structure
revealed that the luxS mutant biofilms adopted a much more granular
appearance, rather than the relatively smooth, confluent layer
normally seen in wild type. These results demonstrate that
LuxS-dependent signal play an important role in biofilm formation
of S. mutans.
Example 1
Material and Methods
[0048] Bacterial Strains and Culture Conditions
[0049] All bacterial strains used in this study and their
characteristics are listed in Table 1. All S. mutans strains were
grown in brain heart infusion media (Difco) or on brain heart
infusion agar plates. luxS deletion mutants were grown using the
same media supplemented with 15 .mu.g/mL erythromycin. All S.
mutans strains were grown anaerobically at 37.degree. C. E. coli
cells were grown in Luria-Bertani (LB) medium with aeration at
37.degree. C. E. coli cells carrying plasmids were grown in LB
medium containing 100 .mu.g/mL erythromycin. V. harveyi BB170
(sensor 1.sup.-, sensor 2.sup.+) was kindly provided by B. Bassler
(Princeton University) and grown in AB medium (37) overnight at
30.degree. C.
1TABLE 1 Bacterial strains used in this study Strain Relevant
Characteristics Reference S. mutans 25175 WT Em.sup.s ATCC S.
mutans GS-5 WT Em.sup.s (16) JM03 .DELTA.luxS Em.sup.r in 25175
background This work JM01 .DELTA.luxS Em.sup.r in GS-5 background
This work E. coli DH5.alpha. supE44 .DELTA.lacU169
(.PHI.80lacZ.DELTA.M15) (17) hsdR17 recA1 endA1 gyrA96 thi-1 relA1
E. coli XL1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 (3) supE44 relA1
lac [F' proAB lacI.sup.qZDM15 Tn10(Tet.sup.r)]
[0050] Cloning and Analyses of the S. mutans luxS Gene
[0051] A 990-bp DNA fragment containing the luxS gene from S.
mutans strain 25175 was PCR amplified from genomic DNA using the
primers WTlux5 (5'-GATGCTGCACGCTCTGTC-3') (SEQ ID NO. 6) and WTlux3
(5'-GCAGTTAGGGTATCCATCC-3') (SEQ ID NO. 7). Primer sequences were
designed using sequence data obtained from the S. mutans Genome
Sequencing Project, University of Oklahoma (B. A. Roe, R. Y. Tian,
H. G. Jia, Y. D. Qian, S. P. Lin, S. Li, S. Kenton, H. Lai, J. D.
White, R. E. McLaughlin, M. McShan, D. Ajdic and J. Ferretti.
http://www.genome.ou.edu- /smutans.html). The resulting fragment
was cloned into the TOPO TA cloning vector (Invitrogen) and
sequenced.
[0052] RNA Isolation and RT-PCR
[0053] S. mutans total RNA was isolated as follows. 25 mL cultures
were grown overnight as previously described. Cells were
centrifuged and resuspended in 1.5 mL of TE buffer and then lysed
using a Mini-Bead Beater 8 according to manufacturer's
instructions. 150 .mu.L of lysate was then passed through a
Qiashredder column (Qiagen) and 100 .mu.L of the resulting lysate
was used for total RNA isolation with the RNeasy mini kit (Qiagen).
cDNA buffer was added to RNA samples to obtain a 1.times. solution
and 3 .mu.L of RQ1 RNase free DNase was added to the sample and
incubated overnight at 37.degree. C. Reverse Transcription was
performed according to manufacturer's protocol using random
hexamers.
[0054] AI-2 Assay
[0055] The AI-2 luminescence reporter assay was performed
essentially as described (38), with the following modifications. To
obtain cell free conditioned media, S. mutans was grown overnight
as described. Stationary phase cells were resuspended in AB media
to an OD.sub.600 of 0.4. Cells were then incubated at 37.degree. C.
with aeration for 3 hrs. After the incubation period, cells were
pelleted by centrifugation, and the resulting supernatant was
filtered through a 0.22 mm pore sized filter (Millipore). The cell
free conditioned media was either used immediately or stored at
-20.degree. C.
[0056] To determine luminescence, an overnight culture of V.
harveyi BB 170 was diluted 1:1000 into fresh AB medium and 180
.mu.L of cells was added to each 1.5 mL microfuge tube. Conditioned
media (20 .mu.L) was then added to the cells at a 10% (vol/vol)
final concentration. Positive control samples were obtained by
adding cell free conditioned media from an overnight culture of V.
harveyi BB170 to a final concentration of 10%. In some cases,
conditioned media from a wildtype culture of S. mutans served as an
additional positive control.
[0057] To determine levels of background luminescence, a sample
containing 200 .mu.L of 1:1000 diluted V. harveyi was also
included. In some cases, E. coli DH5.alpha. served as a negative
control. All samples were measured hourly until peak induction at
the 3 hr time point. Measurements were collected using a TD 20/20
luminometer and expressed as arbitrary luminescence units.
[0058] Construction and Analyses of S. mutans luxS Mutants
[0059] 2 (1 Kb) fragments containing regions of DNA immediately
upstream and downstream of the luxS translational start and stop
codons respectively were amplified from genomic DNA template using
the primers 2XupF (5'-GCGGATCCTCAAGCTCTCAAGCGTTCGG-3') (SEQ ID NO.
8) and 2XupR (5'-CGAGATCTATAAGACGGACATAAGGGGC-3') (SEQ ID NO. 9) as
well as 2XdownF (5'-GCCTCGAGCAGATGATCCTTTTGAGCGTC-3') (SEQ ID NO.
10) and 2XdownR (5'-CGTCTAGACGGATGCAAAGAGAACGAAG-3') (SEQ ID NO.
11). Primer sequences were designed using sequence data obtained
from the S. mutans Genome Sequencing Project, University of
Oklahoma (http://www.genome.ou.edu/smut- ans.html). The resulting
fragments were cloned into the TOPO TA cloning vector
(Invitrogen).
[0060] To obtain the necessary fragments, four separate restriction
digests were constructed: the upstream fragment was cut from the
vector using BamHI and BglII, the downstream fragment was cut from
the vector using XhoI and XbaI, the erythromycin cassette was cut
from the plasmid pJT10 (unpublished plasmid by J. P Tsai and W.
Shi) using BglII and XhoI, and the pUC19 vector was cut with BamHI
and XbaI. The resulting fragments were all gel purified (Qiagen),
precipitated, and added to one mass ligation reaction. The
resulting construct was then checked by restriction analysis and
PCR for the proper configuration of the knockout vector
(pUCluxKO).
[0061] Next, the plasmid was linearized with the unique cutting
enzyme AatII and transformed into S. mutans. Transformants were
selected for resistance to 15 .mu.g/mL erythromycin. Confirmation
of DNA integration was performed by PCR using primers IntluxF
(5'-AAGAGTTTGGACCTAAAGGC-3') (SEQ ID NO. 12), IntluxR
(5'-CCCACAGGACTCAATAGTTG-3') (SEQ ID NO. 13), UpluxF
(5'-CTCGACGAATAGGATCAAAGC-3') (SEQ ID NO. 14), DownluxR
(5'-GAGCCATCACACAGCAAAAAC-3') (SEQ ID NO. 15), ermA
(5'-AGTGTGTTGATAGTGCAGTATC-3') (SEQ ID NO. 16), and ermM
(5'-GAAGCTGTCAGTAGTATACC-3') (SEQ ID NO. 17). All mutants confirmed
by PCR were further analyzed for their ability to produce AI-2
using the methods described above.
[0062] Growth of In Vitro Biofilm
[0063] Biofilms of S. mutans were grown as follows. Individual
sterile culture dishes were filled with 2.5 mL of brain heart
infusion broth supplemented with 1% (w/v) sucrose. Next, a sterile
18 mm glass microscope cover slip was added to each dish and the
culture dish was covered. Each sample was then inoculated with a
defined volume of overnight culture. The dishes were incubated
anaerobically at 37.degree. C. overnight.
[0064] Microscopic Analyses of In Vitro Grown Biofilm
[0065] Glass cover slips containing attached biofilm were removed
from overnight cultures and rinsed briefly with water. These could
be directly viewed using phase contrast and darkfield microscopy.
For fluorescently labeled samples, the biofilms were first removed
from the culture dish and placed into another dry culture dish.
Next, 20 .mu.L of anti-S. mutans mouse monoclonal antibody solution
(SWLA1) was added to the attached biofilm in each culture dish and
incubated at room temperature for 30 minutes (Shi, W., et al.,
Hybridoma, 17:365-71 (1998)).
[0066] After the incubation period, 5 .mu.L of 2.degree. antibody
(FITC conjugated goat anti-mouse) was added to the biofilms and
incubated at room temperature for an additional 10 minutes.
Finally, the cover slip was briefly rinsed with water to remove
excess antibodies and unattached cells and the sample was
immediately imaged using fluorescence microscopy.
[0067] Treatment of In Vitro Biofilm with SDS and Antibiotics
[0068] Biofilms were grown overnight using previously described
conditions. For treatment with SDS, cover-slips were removed from
overnight incubation and rinsed briefly. These were then placed
into a fresh culture dish and 2 mL of sterile, 1% (w/v) SDS
solution was added to each dish. The biofilms were placed on a
standard shaker set at 150 rpm for one hour at room temperature.
Next, supernatant samples were checked at 40.times. magnification
to confirm that cells were fully individualized and not connected
in chains. These samples were measured for their OD.sub.600 values.
For treatment with antibiotics, biofilms were again grown under
standard conditions overnight. The following day, the spent media
was changed and replaced with BHI supplemented with 1% (w/v)
sucrose solution. Ampicillin was added at either 50 .mu.g/mL or 500
.mu.g/mL. These biofilms were allowed to grow overnight under
anaerobic conditions at 37.degree. C. The following day, biofilms
were removed from incubation and sonicated until the cells were
fully dispersed. A 10 fold dilution of each sample was plated on
non-selective BHI agar plates and incubated anaerobically overnight
at 37.degree. C.
Example 2
Identification and Isolation of S. mutans luxS Gene
[0069] To determine whether S. mutans may posses an interspecies
quorum system, it was first necessary to identify a candidate
ortholog of luxS, the enzyme required for AI-2 production. Using
the luxS gene from Vibrio harveyi, we performed a BLAST search of
the University of Oklahoma Streptococcus mutans Genome Sequence
Database. A candidate open reading frame was identified.
[0070] The ORF appears to be an isolated gene (no other convincing
ORF's nearby) and encodes a protein of 160 amino acids, which is
similar in size to other reported LuxS proteins. It is homologous
to the V. harveyi LuxS protein with 38% amino acid identity and 57%
similarity.
[0071] Using this sequence data, primers were designed to amplify a
region about 500 bp upstream of the translation start site and
about 100 bp downstream of the translational stop site. This
fragment was PCR amplified, cloned into the TOPO TA cloning vector,
and sequenced to confirm the identity of the gene. After the
fragment was confirmed to be the same ORF identified in the
Sequence Database, an NCBI PSI BLAST search of the candidate gene
was conducted.
[0072] The results yielded strong homologies to numerous LuxS
proteins from other Gram positive and Gram negative bacteria. The
strongest homologies (identity/similarity) were to other Gram
positive species such as Streptococcus pyogenes (84%/92%),
Streptococcus pneumoniae (83%/91%), Lactococcus lactis (64% 179%),
and Clostridium perfringens (45%/64%), but there were also
significant homologies to Gram negative species such as Neisseria
meningitidis (36%/58%), Escherichia coli (37%/59%), and Haemophilus
influenzae (37%/58%). A multiple alignment of the putative S.
mutans LuxS protein and those from V. harveyi, E. coli, S.
pyogenes, and B. subtilis demonstrated a high degree of similarity
(FIG. 1).
[0073] Of greatest interest was the location of several highly
conserved amino acids (H, H, & C), which are reported to
coordinate a Zn.sup.+2 ion and form the catalytic center of the
protein (19). These amino acids and several others that are
reportedly invariant are all conserved in the S. mutans LuxS
protein (FIG. 1).
Example 3
Complementation of an E. coli luxS Mutant with S. mutans luxS
Gene
[0074] After confirming the identity of the candidate ORF, it was
necessary to determine whether this gene also had the
characteristic AI-2 synthase activity. This was accomplished by
complementing an AI-2 production defect in E. coli DH5.alpha.. This
strain of E. coli is known to have a frameshift mutation in its
luxS gene. Therefore, a plasmid containing the luxS gene and some
upstream sequence was transformed into DH5.alpha. and AI-2 activity
was measured using the reporter assay described by Surrette et al
(Surette, M. G., et al., Proc Natl Acad Sci USA, 95:7046-50
(1998)).
[0075] As shown in FIG. 2, our assay confirmed that E. coli
DH5.alpha. was AI-2 negative and also demonstrated that the
presence of the luxS containing plasmid was sufficient to induce
luminescence 89-fold over background.
Example 4
Secretion of an AI-2-Like Signal by S. mutans
[0076] To determine whether S. mutans had endogenous AI-2 activity,
we again employed the AI-2 reporter assay. Initial screens using
this assay failed to demonstrate any convincing AI-2 activity.
These first experiments were all performed as had been described in
previous reports. Cells were grown to various OD.sub.600 values
using standard growth media and the resulting conditioned media was
used as a source of AI-2 molecules. However, these experiments
consistently yielded background levels of luminescence.
[0077] In E. coli, it had been demonstrated that the presence of
glucose in the growth media caused a strong induction of AI-2
(Surette, M. G., et al., Proc Natl Acad Sci USA, 95:7046-50
(1998)). Therefore, we decided to try adding glucose as well as
sucrose (S. mutans preferred carbon source) to the growth media in
an effort to demonstrate AI-2 production. Since S. mutans is an
acidogenic bacterium, pH readings were taken to ensure that there
were no negative effects due to lowered pH. Interestingly, these
experiments consistently yielded lower than background levels of
luminescence (FIG. 3).
[0078] In an effort to circumvent this problem, we decided to
resuspend overnight cultures in the AI-2 assay media at various
OD.sub.600 ranges. This media only allows for very limited growth
of S. mutans, but is able to keep the cells alive long enough for
the production of AI-2 signal molecules. After assaying samples
produced in this manner, it was immediately possible to measure
induced luminescence. Samples assayed at mid to late log growth
phase had the strongest induction over background, while the
induction tended to drop at stationary phase. Mid to late log
samples typically produced about 25-fold induction of the reporter
strain (V. harveyi) luciferase operon expression over background
levels (FIG. 3). As a further confirmation, luxS was shown to be
expressed in S. mutans via RT-PCR.
Example 5
Construction of S. mutans luxS Mutants
[0079] After confirming that this ORF was a functional luxS gene
and that it was involved in the production of AI-2 signal
molecules, we decided to disrupt the function of this gene by
allelic replacement to check for any resulting phenotypic changes.
luxS was deleted using a double crossover construct as illustrated
in FIG. 4A and described in Example 1. The double crossover event
was confirmed by various PCR reactions. As a further confirmation
of the construct, we tested these mutants for the loss of AI-2
activity. As shown in FIG. 4B, wildtype S. mutans had a
luminescence induction of about 25 fold, while the mutant retained
essentially background levels of luminescence.
Example 6
General Phenotypic Characterization of S. mutans luxS Mutants
[0080] After confirmation of the deletion of luxS and subsequent
loss of AI-2 activity, the next step was to quantify any resulting
physiological changes in the luxS mutant. When the mutant colonies
were plated, there were no obvious phenotypic differences in colony
morphology. In batch culture there was no obvious difference in
growth rate, nutrient requirements, or acid production.
Example 7
Altered Biofllm Structure of the S. mutans luxS Mutants
[0081] Our next investigation of mutant phenotypes was to determine
if there were any alterations of biofilm structure as a result of
loss of AI-2 production. Both wild-type and mutant cells were able
to form a biofilm when grown on a solid surface overnight.
[0082] Upon visual inspection, there was a noticeable difference in
biofilm structure from the wild-type. Without the aid of
magnification, wild-type biofilm generally has a very confluent
appearance with no major discernable features. In contrast, the
luxS mutant biofilm had a very rough texture. Under 20.times. and
40.times. magnification, this difference is even more apparent.
Wild-type biofilms are very uniform with complete coverage of the
attached surface. They also tend to have relatively small
aggregates spread fairly evenly throughout the biofilm matrix. luxS
mutant biofilms are quite different. Their organization seems much
more heterogeneous. There were noticeable large gaps in the biofilm
matrix and the cell aggregates appeared much larger. Using
fluorescence imaging, there is a clear indication that the sizes of
mutant aggregates tended to be much larger than those of
wild-type.
[0083] As biofilms are known to be very resistant to detergents and
biocides, we were also interested to determine if this property was
influenced by the luxS mutation. Overnight biofilms of wildtype and
the luxS mutant were incubated in a 1% solution of SDS and shaken
at 150 rpm for one hour. These supernatants were then checked by
microscopy to ensure that cells were not clumped, and subsequently,
measured for the OD.sub.600. It was found that the wildtype
supernatants had an OD.sub.600 value that averaged about 6 fold
greater than that of the mutant (FIG. 5B), which suggested that
luxS mutant biofilms were more resistant to detergent treatment. We
also treated biofilms of wildtype and the luxS mutant with the
antibiotic ampicillin at 50 .mu.g/mL or 500 .mu.g/mL for 16 hours.
We found that very few (<1%), if any, wildtype cells survived
treatment with 50 .mu.g/mL ampicillin and that none survived the
treatment with 500 .mu.g/mL. In contrast, numerous cells (>10%)
within the luxS mutant biofilms survived the treatment with 50
.mu.g/mL ampicillin and even with 500 .mu.g/mL ampicillin.
[0084] Within the past couple of years, there has been a plethora
of data describing various physiological functions from both Gram
positive and Gram negative species which are subject to regulation
by luxS (Chung, W. O., et al., J Bacteriol, 183:3903-9 (2001); Day,
W. A., Jr., et al., Infect Immun, 69:15-23 (2001); Fong, K. P., et
al., Infect Immun, 69:7625-34 (2001); Lyon, W. R., et al., Mol
Microbiol, 42:145-57 (2001); and Sperandio, V., et al., Proc Natl
Acad Sci USA, 96:15196-201 (1999)). Much of the reported data has
supported the hypothesis that luxS is somehow involved in
regulating virulence factor expression. Furthermore, there has not
been a reported scenario in which mutating this gene has lead to
severe growth impairment, which suggests that the production of
AI-2 is not a requirement for basic metabolic processes.
[0085] Our current findings are consistent with these same trends.
After deletion of the luxS gene, there were no noticeable changes
in growth patterns or basic nutrient requirements. However, S.
mutans is a predominantly biofilm dwelling organism and as such
depends on its biofilm production for virulence in the oral cavity.
The involvement of luxS in the proper development of S. mutans
biofilms also yields some insight into the role of interspecies
communication in multispecies biofilm formation. S. mutans normally
grows amongst hundreds of other competing species of oral bacteria
and must therefore employ strategies to survey and respond to other
species that compete for control of available ecological niches in
the mouth.
[0086] One possible strategy to accomplish this goal would be
through the use of luxS based interspecies signaling. We believe
that as an early colonizer of the tooth surface, AI-2 signal
molecules is an important factor in regulating biofilm related gene
expression to help modulate energy utilization for growth in an
extremely competitive enviroment.
[0087] Through a search of the S. mutans genome database, we were
able to find a candidate luxS ortholog. Despite having a gene whose
encoded protein aligned exceedingly well with other known LuxS
proteins, initial attempts to demonstrate the production of AI-2
molecules all seemed to suggest that they were not produced.
Indeed, there are reports of other luxS containing bacteria that
have not been shown to induce the AI-2 reporter assay (Frias, J.,
et al., Infect Immun, 69:3431-4 (2001) and Surette, M. G., et al.,
Proc Natl Acad Sci USA, 96:1639-44 (1999)). It was especially
perplexing to find that the presence of glucose and sucrose in the
growth media caused the AI-2 reporter assay to yield values below
background levels, while glucose was known to cause a potent
induction of AI-2 activity in E. coli.
[0088] Part of the answer came from the media itself. It seems that
detectable AI-2 activity drops in rich media and is potently
inhibited in the presence of glucose and to an even greater extent
with sucrose. This phenomenon may explain why a recent screen for
AI-2 activity in various oral pathogens failed to demonstrate AI-2
activity in S. mutans strain 25175 (Frias, J., et al., Infect
Immun, 69:3431-4 (2001)).
[0089] There also exists the possibility that AI-2 is still
produced in rich media and/or in the presence of sugar, but the
reporter assay is inhibited by some factor(s) secreted by S. mutans
when grown under these conditions. Indeed, S. mutans is known to
produce a battery of various inhibitory molecules such as
lantibiotics and non-lantibiotic bacteriocins (Chen, P., et al.,
Appl Enviro Microbiol, 65:1356-60 (1999); Qi, F., et al., Appl
Environ Microbiol, 67:15-21 (2001); and Qi, F., et al., Appl
Environ Microbiol, 65:3880-7 (1999)). In addition, it is also known
that in the presence of sugars, S. mutans has a distinct growth
advantage over other competing oral bacteria. Therefore, it is
possible that sugar stimulates S. mutans to produce an inhibitor
that affected either luciferase production in the AI-2 assay or
perhaps even an inhibitor that acted at level of the AI-2 signaling
process. Even though an AI-2 related inhibitory signal in S. mutans
is currently unknown, its production could give additional
explanations for S. mutans ability to gain a growth advantage over
competitors within its multispecies biofilm.
[0090] Our data show that both wild-type and the luxS mutant of S.
mutans are able to form biofilms on solid surfaces. This is
consistent with previous reports (Wen, Z. T., et al., Appl Environ
Microbiol, 68:1196-203 (2002)). Our investigation demonstrates that
the luxS mutant has several altered biofilm phenotypes: increased
size of cell aggregates, altered biofilm structure, and an
increased biofilm resistance to detergents and antibiotics. These
phenotypes reveal that luxS has a regulatory role on one or more
genes related to biofilm formation. In S. mutans, EPS consists of
insoluble glucans, which are primarily synthesized by the activity
of the GtfB enzyme. Glucans make the cells more generally adherent
in a nonspecific manner, but are also known to interact with glucan
binding proteins for specific interactions (Hazlett, K. R., et al.,
Infect Immun, 67:3909-14 (1999) and Mattos-Graner, R. O., et al.,
Infect Immun, 69:6931-41 (2001)). Therefore, the observed
phenotypes can be partially due to a greater production of glucan,
an increase in specific receptors for glucan or other cell wall
components, or possibly a combination of both factors. These
questions are currently being addressed using a proteomics
approach.
[0091] In summary, we have identified a luxS ortholog in S. mutans
and demonstrated a corresponding AI-2 activity in the AI-2 assay.
When luxS was inactivated, AI-2 activity was abolished with
concomitant changes in biofilm structure and resistance to
detergents and antibiotics. Taken together, this study provides
evidence for the involvement of LuxS in bacterial biofilm
formation. It also demonstrates that AI-2 molecules or its analogs
could be used to alter biofilm structure in S. mutans and/or make
the bacteria within its biofilm more accessible to detergent and/or
antibiotic treatments.
[0092] Although the invention has been described with reference to
the presently preferred embodiment, it should be understood that
various modifications can be made without departing from the spirit
of the invention. Accordingly, the invention is limited only by the
following claims.
Sequence CWU 1
1
17 1 160 PRT Streptococcus mutans 1 Met Thr Lys Glu Val Thr Val Glu
Ser Phe Glu Leu Asp His Ile Ala 1 5 10 15 Val Lys Ala Pro Tyr Val
Arg Leu Ile Ser Glu Glu Phe Gly Pro Lys 20 25 30 Gly Asp Leu Ile
Thr Asn Phe Asp Ile Arg Leu Val Gln Pro Asn Glu 35 40 45 Asp Ser
Ile Pro Thr Ala Gly Leu His Thr Ile Glu His Leu Leu Ala 50 55 60
Lys Leu Ile Arg Gln Arg Ile Asp Gly Met Ile Asp Cys Ser Pro Phe 65
70 75 80 Gly Cys Arg Thr Gly Phe His Leu Ile Met Trp Gly Lys His
Thr Thr 85 90 95 Thr Gln Ile Ala Thr Val Ile Lys Ala Ser Leu Glu
Glu Ile Ala Asn 100 105 110 Thr Ile Ser Trp Lys Asp Val Pro Gly Thr
Thr Ile Glu Ser Cys Gly 115 120 125 Asn Tyr Lys Asp His Ser Leu Phe
Ser Ala Lys Glu Trp Ala Lys Leu 130 135 140 Ile Leu Lys Gln Gly Ile
Ser Asp Asp Pro Phe Glu Arg His Leu Val 145 150 155 160 2 172 PRT
Vibrio harveyi 2 Met Pro Leu Leu Asp Ser Phe Thr Val Asp His Thr
Arg Met Asn Ala 1 5 10 15 Pro Ala Val Arg Val Ala Lys Thr Met Gln
Thr Pro Lys Gly Asp Thr 20 25 30 Ile Thr Val Phe Asp Leu Arg Phe
Thr Ala Pro Asn Lys Asp Ile Leu 35 40 45 Ser Glu Lys Gly Ile His
Thr Leu Glu His Leu Tyr Ala Gly Phe Met 50 55 60 Arg Asn His Leu
Asn Gly Asp Ser Val Glu Ile Ile Asp Ile Ser Pro 65 70 75 80 Met Gly
Cys Arg Thr Gly Phe Tyr Met Ser Leu Ile Gly Thr Pro Ser 85 90 95
Glu Gln Gln Val Ala Asp Ala Trp Ile Ala Ala Met Glu Asp Val Leu 100
105 110 Lys Val Glu Asn Gln Asn Lys Ile Pro Glu Leu Asn Glu Tyr Gln
Cys 115 120 125 Gly Thr Ala Ala Met His Ser Leu Asp Glu Ala Lys Gln
Ile Ala Lys 130 135 140 Asn Ile Leu Glu Val Gly Val Ala Val Asn Lys
Asn Asp Glu Leu Ala 145 150 155 160 Leu Pro Glu Ser Met Leu Arg Glu
Leu Arg Ile Asp 165 170 3 170 PRT Escherichia coli 3 Met Pro Leu
Leu Asp Ser Phe Thr Val Asp His Thr Arg Met Glu Ala 1 5 10 15 Pro
Ala Val Arg Val Ala Lys Thr Met Asn Thr Pro His Gly Asp Ala 20 25
30 Ile Thr Val Phe Asp Leu Arg Phe Cys Val Pro Asn Lys Glu Val Met
35 40 45 Pro Glu Arg Gly Ile His Thr Leu Glu His Leu Phe Ala Gly
Phe Met 50 55 60 Arg Asn His Leu Asn Gly Asn Gly Val Glu Ile Ile
Asp Ile Ser Pro 65 70 75 80 Met Gly Cys Arg Thr Gly Phe Tyr Met Ser
Leu Ile Gly Thr Pro Asp 85 90 95 Glu Gln Arg Val Ala Asp Val Trp
Lys Ala Ala Met Glu Asp Val Leu 100 105 110 Lys Val Gln Asp Gln Asn
Gln Ile Pro Glu Leu Asn Val Tyr Gln Cys 115 120 125 Gly Thr Tyr Gln
Met His Ser Leu Gln Glu Ala Gln Asp Ile Ala Arg 130 135 140 Ser Ile
Leu Glu Arg Asp Val Arg Ile Asn Ser Asn Glu Glu Leu Ala 145 150 155
160 Leu Pro Lys Glu Lys Leu Gln Glu Leu His 165 170 4 160 PRT
Streptococcus pyogenes 4 Met Thr Lys Glu Val Ile Val Glu Ser Phe
Glu Leu Asp His Thr Ile 1 5 10 15 Val Lys Ala Pro Tyr Val Arg Leu
Ile Ser Glu Glu Phe Gly Pro Lys 20 25 30 Gly Asp Arg Ile Thr Asn
Phe Asp Val Arg Leu Val Gln Pro Asn Gln 35 40 45 Asn Ser Ile Glu
Thr Ala Gly Leu His Thr Ile Glu His Leu Leu Ala 50 55 60 Lys Leu
Ile Arg Gln Arg Ile Asp Gly Met Ile Asp Cys Ser Pro Phe 65 70 75 80
Gly Cys Arg Thr Gly Phe His Leu Ile Met Trp Gly Lys His Ser Ser 85
90 95 Thr Asp Ile Ala Lys Val Ile Lys Ser Ser Leu Glu Glu Ile Ala
Thr 100 105 110 Gly Ile Thr Trp Glu Asp Val Pro Gly Thr Thr Leu Glu
Ser Cys Gly 115 120 125 Asn Tyr Lys Asp His Ser Leu Phe Ala Ala Lys
Glu Trp Ala Gln Leu 130 135 140 Ile Ile Asp Gln Gly Ile Ser Asp Asp
Pro Phe Ser Arg His Val Ile 145 150 155 160 5 157 PRT Bacillus
subtilis MISC_FEATURE (84)..(84) Xaa is any amino acid 5 Met Pro
Ser Val Glu Ser Phe Glu Leu Asp His Asn Ala Val Val Ala 1 5 10 15
Pro Tyr Val Arg His Cys Gly Val His Lys Val Gly Thr Asp Gly Val 20
25 30 Val Asn Lys Phe Asp Ile Arg Phe Cys Gln Pro Asn Lys Gln Ala
Met 35 40 45 Lys Pro Asp Thr Ile His Thr Leu Glu His Leu Leu Ala
Phe Thr Ile 50 55 60 Arg Ser His Ala Glu Lys Tyr Asp His Phe Asp
Ile Ile Asp Ile Ser 65 70 75 80 Pro Met Gly Xaa Gln Thr Gly Tyr Tyr
Leu Val Val Ser Gly Glu Thr 85 90 95 Thr Ser Ala Glu Ile Val Asp
Leu Leu Glu Asp Thr Met Lys Glu Ala 100 105 110 Val Glu Ile Thr Glu
Ile Pro Ala Ala Asn Glu Lys Gln Cys Gly Gln 115 120 125 Ala Lys Leu
His Asp Leu Glu Gly Ala Lys Arg Leu Met Arg Phe Trp 130 135 140 Leu
Ser Gln Asp Lys Glu Glu Leu Leu Lys Val Phe Gly 145 150 155 6 18
DNA Artificial sequence PCR primer 6 gatgctgcac gctctgtc 18 7 19
DNA Artificial sequence PCR primer 7 gcagttaggg tatccatcc 19 8 28
DNA Artificial sequence Amplification primer 8 gcggatcctc
aagctctcaa gcgttcgg 28 9 28 DNA Artificial sequence Amplification
primer 9 cgagatctat aagacggaca taaggggc 28 10 29 DNA Artificial
sequence Amplification primer 10 gcctcgagca gatgatcctt ttgagcgtc 29
11 28 DNA Artificial sequence Amplification primer 11 cgtctagacg
gatgcaaaga gaacgaag 28 12 20 DNA Artificial sequence PCR primer 12
aagagtttgg acctaaaggc 20 13 20 DNA Artificial sequence PCR primer
13 cccacaggac tcaatagttg 20 14 21 DNA Artificial sequence PCR
primer 14 ctcgacgaat aggatcaaag c 21 15 21 DNA Artificial sequence
PCR primer 15 gagccatcac acagcaaaaa c 21 16 22 DNA Artificial
sequence PCR primer 16 agtgtgttga tagtgcagta tc 22 17 20 DNA
Artificial sequence PCR primer 17 gaagctgtca gtagtatacc 20
* * * * *
References